Serum GFAP and NFL as biomarkers for disease activity, severity and disability in NMOSD
- 21 July 2025
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (8) , 1-11
Abstract
Objective Serum glial fibrillary acidic protein (sGFAP) and neurofilament light chain (sNfL) levels are potential biomarkers for disease activity and disability in Neuromyelitis Optica Spectrum Disorder (NMOSD), respectively; however, their clinical applications in NMOSD remain unclear. Therefore, this study aims to investigate the correlation between sGFAP and sNfL levels and the activity, severity of attacks, disability in patients with NMOSD. Methods SGFAP and sNfL levels were measured in healthy controls (HCs) (n = 20) and patients with NMOSD (n = 86; 50 during attack and 50 in remission) using ultrasensitive single-molecule array assays. The relationships between the two biomarkers and different stages of NMOSD, the severe attacks, the Expanded Disability Status Scale (EDSS) scores, and the prognosis were analyzed. Results SNfL and sGFAP levels were significantly higher in patients with NMOSD than in HCs in the acute and remission phases (p < 0.05). The sGFAP level was higher in the acute phase than in the remission phase (P < 0.001). SNfL and sGFAP levels were higher in the severe myelitis attack group than in the severe optic neuritis attack group (p < 0.05). The EDSS ≥ 6 NMOSD group had significantly higher sNfL and sGFAP levels than the EDSS < 6 group (p < 0.05). SNfL and sGFAP levels in acute and remission stages increased with increasing EDSS scores (p < 0.05). SGFAP could discriminate patients with NMOSD with relapse from those under remission (p < 0.001). Conclusion sNfL and sGFAP may serve as biomarkers for NMOSD severity, activity, and motor disability.Keywords
This publication has 29 references indexed in Scilit:
- Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG–Positive Neuromyelitis Optica Spectrum DisorderJAMA Neurology, 2025
- Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorderJournal of Neurology, 2024
- Neurofilaments as biomarkers in neurological disorders — towards clinical applicationNature Reviews Neurology, 2024
- A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorderJournal of Neurology, 2022
- Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation studyThe Lancet Neurology, 2022
- Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder BiomarkerAnnals of Neurology, 2021
- Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseasesAnnals of Clinical and Translational Neurology, 2020
- Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human diseaseBrain Research, 2015
- Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis opticaActa Neuropathologica, 2013
- Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cellsBiochemical and Biophysical Research Communications, 2010